STL Index for: Imiquimod
Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada
Chlormethine gel, a topical antineoplastic agent, has shown safety and efficacy in phase II trials and real-world data for treating adult Mycosis Fungoides patients. Despite potential skin-related side effects, chlormethine gel offers a convenient, skin-directed treatment for stage IA and IB MF-CTCL, addressing an unmet need in Canada.
Tirbanibulin for the Treatment of Actinic Keratosis: A Review
Tirbanibulin effectively and completely cleared AK lesions with a 5-day application period while demonstrating a favorable safety profile, mild AEs, improved tolerability, and long-term results, making it a promising field therapy for AKs.
Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions
HPV vaccines (Gardasil and Cervarix) may indeed have a therapeutic role in patients who suffer from dermatologic conditions that are associated with various strains of HPV.
Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review
Given our current options for the treatment of Seborrheic Keratoses include only more invasive, non-topical therapies, Hydrogen Peroxide Topical Solution (40%) fills a void in our therapeutic repertoire as the first FDA-approved topical therapy for SKs.
Management of Non-melanoma Skin Cancers in Canada
A summary of the most comprehensive and up to date guideline for treating non-melanoma skin cancer in Canada. Background, primary prevention, actinic keratosis, managing basal cell carcinoma, and squamous cell carcinoma, are covered.
Sinecatechins 10% Ointment: A Green Tea Extract for the Treatment of External Genital Warts
External genital warts resulting from HPV are a common sexually transmitted infection. This article reviews data on Sinecatechins 10% ointment (a Green Tea extract), a new botanically based patient-administered therapy for external genital warts.
An Update on the Clinical Management of Cutaneous Molluscum Contagiosum
Molluscum contagiosum is a poxvirus infection of the skin that is commonly observed in children. This articles discusses the molluscum contagiosum virus (MCV), its pathogenesis, mechanism, and treatment modalities.
Clinical Management of External Genital Warts
External genital warts (EGW) is a common sexually transmitted infection (STI) affecting millions of individuals worldwide. It is likely the most frequent STI in both Canada and the US. Treatment options and vaccination is discussed.
Actinic Keratosis: A Practical Overview
Actinic keratosis (AK) is a prevalent skin condition that warrants 5.2 million office visits in the US each year. Various treatments for AK, both local and field therapy, and their appropriate use are discussed in this article.
The Role of Imiquimod 3.75% Cream in the Treatment of External Genital Warts
Imiquimod 3.75% cream has recently been approved by both the FDA and Health Canada for the treatment of external genital warts. This article is an overview of EGW, phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and comparison with imiquimod 5% cream.
Therapeutic Update on External Genital Warts (Pharmacist Edition)
External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the pathogenesis of EGW, impact on patients, therapeutics, vaccination, and other topics.
A Practical Approach to Classification and Treatment of Scars
This paper focuses on a comprehensive and practical approach to classifying and managing scars in terms of colour and texture, and discusses topical treatments accessible to family physicians in more detail.
Therapeutic Update on External Genital Warts
External genital warts (EGW) are a common infection caused primarily by human papillomavirus (HPV) types 6 and 11. This article discusses the impact of EGW on the patient, co-factors for other STIs, and therapies for EGW.
Update on Drugs and Drug News: June 2011
Update on Peginterferon alfa-2b (Sylatron™), Imiquimod 3.75% cream (Zyclara®), experienced recurrence 12 weeks after therapy. (Adapalene 0.1% + benzoyl peroxide 2.5% gel Tactuo™), Collagenase clostridium histolyticum (Xiapex®), and updates on generic drugs.
Therapeutic Advances in Cutaneous T-Cell Lymphoma
A variety of novel therapeutic modalities have recently become available for patients with cutaneous T cell lymphoma (CTCL). Here, we offer a brief overview of these agents and discuss their place in the spectrum of current therapies for CTCL.
Update on the Management of Actinic Keratoses
Actinic keratoses (AKs), or solar keratoses, are pre-malignant cutaneous lesions that predominantly manifest in sun-exposed areas. They are one of the most common skin conditions seen by dermatologists, preceded only by acne vulgaris and dermatitis.
Update on the Management of Actinic Keratoses (Pharmacist Edition)
Actinic keratoses (AKs), or solar keratoses, are pre-malignant cutaneous lesions that predominantly manifest in sun-exposed areas. This article covers treatment regimens, sun protection, and the role that physicians play in improving patient awareness.
Current Management of Actinic Keratoses
An actinic keratosis is a pre-malignant cutaneous lesion that frequently manifests in sun-exposed areas of the skin as a small, rough, scaly erythematous papule. Therapy choices are guided by efficacy, adverse effects, cosmetic results, and patient compliance.
A Review of Therapeutic Options for Genital Warts
Condylomata acuminata (genital or venereal warts) pose a significant health concern, especially amongst young adults. External genital warts (EGWs) are caused by infection with the human papillomavirus (HPV), the same virus that causes the majority of cervical cancers.
Safety, Efficacy & Recurrence Rates of Imiquimod Cream 5% for Treatment of Anogenital Warts
Imiquimod 5% cream (Aldara™, Graceway Pharmaceuticals) is an immune response modifier used for the topical treatment of anogenital warts in non-HIV-infected patients. Several randomized controlled trials have demonstrated that imiquimod 5% cream is a safe and efficacious treatment.
A Review of Therapeutic Options for Genital Warts (Pharmacist Edition)
Condylomata acuminata (genital or venereal warts) pose a significant health concern, especially amongst young adults. Recent therapeutic advances such as topical immunomodulatory agents and a prophylactic vaccines have significantly broadened the options for management.
New Evidence for the Treatment and Management of Actinic Keratoses (Pharmacist Edition)
Increasingly, patients are seeking medical consultation for the management of photodamage, actinic keratoses (AKs), and nonmelanoma skin cancer (NMSC), which is now a global epidemic. A comparative analysis of various treatment modalities are shown.
New Evidence for the Treatment and Management of Actinic Keratoses
Cutaneous concerns continue to be a significant part of family and specialty practices, as increasingly, patients are seeking medical consultation for the management of photodamage, actinic keratoses, and nonmelanoma skin cancer (NMSC), which is now a global epidemic.
External Genital Warts (Pharmacist Edition)
Human papillomavirus (HPV) is a very common sexually transmitted disease that is associated with a number of benign, premalignant, and frankly malignant lesions of the anogenital tract. Various treatments as well as new vaccines for HPV are discussed.
External Genital Warts
Most HPV infections are asymptomatic and can spontaneously clear on their own. However if treatment is required, there are a number of antiproliferative, destructive, immunomodulatory modalities available. Combination therapies have been shown to be advantageous.
Dosing, Efficacy, Compliance and Cost of Aldara (Imiquimod) Treatment
Dosing, efficacy, compliance and cost of Aldara (Imiquimod) are discussed in the context of genital wart treatment.
Aldara (Imiquimod) Side Effects, Safety and Risks
Imiquimod side effects with reference to Erythema, Edema, Induration, Vesiculation, Excoriation, Scaling and flaking.
Aldara (Imiquimod) Drug and Patient Profile
Imiquimod drug profile including Actinic Keratosis, Bowen’s disease, Squamous cell carcinoma and Genital Warts.
Indications for Aldara (Imiquimod)
Imiquimod was first indicated and used for external genital and perianal warts/ condyloma acuminata. Other HPV warts have also been treated by this drug, often in combination with more conventional therapy including cryotherapy and CO2 laser therapy, in immunocompetent and immunosuppressed patients.
Aldara (Imiquimod) Clinical Experience
Imiquimod was first indicated and used for external genital and perianal warts/ condyloma acuminata. Other HPV warts have also been treated by this drug, often in combination with more conventional therapy including cryotherapy and CO2 laser therapy, in immunocompetent and immunosuppressed patients.
The Forgotten HPV: External Genital Warts
HPV is a very common sexually transmitted disease that is associated with a number of benign, premalignant, and frankly malignant lesions of the anogenital tract. The majority of HPV infections are asymptomatic and are spontaneously cleared by a predominantly cell-mediated immune response.
Immunological Strategies to Fight Skin Cancer
Skin cancer is the most common human cancer, and is currently considered a global epidemic. Recently, there has been a growing interest in immunomodulators, or upregulators of the immune response.
A Practical Guide to Dermatological Drug Use in Pregnancy
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
Imiquimod 5% Cream (Aldara®) in the Treatment of Basal Cell Carcinoma
Skin cancer, the most common human cancer, is now a global epidemic. The most prevalent form of nonmelanoma skin cancer is basal cell carcinoma (BCC), the incidence of which continues to increase prompting development of new treatment modalities designed to add or complement current therapies.
Imiquimod 5% Cream for the Treatment of Actinic Keratoses
Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections.
New Approaches to Surgery of Lentigo Maligna
Lentigo maligna (LM) is a pigmented lesion that occurs most commonly on the sun-exposed skin of the head and neck of an older patient. LM can be difficult to completely remove due to its occasional extensive subclinical extension. The gold standard treatment for LM is margin-controlled excision.
Novel Dermatologic Uses of the Immune Response Modifier Imiquimod 5% Cream
Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders. As an immune response modifier, it has been shown to have potent antiviral and antitumor properties through the stimulation of innate and cell mediated immune pathways.
Imiquimod Applied Topically: A Novel Immune Response Modifier
Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, was approved as a 5% cream (Aldara, 3M Pharmaceuticals) by the US FDA in February 1997, for the treatment of genital and perianal warts.
Imiquimod: An Immune Response Modifier
Imiquimod is an immune response modifier. Studies have shown that it has potent immunomodulatory effects and stimulates human peripheral mononuclear cells to release interferon alpha, sub-types α1,α2, α5, α6, and α8.